USDA Takes Steps Toward Tackling Consolidation in Agriculture
November 8, 2023 — In response to a new package of initiatives announced by the U.S. Department of Agriculture today designed to promote competition — including a rule requiring enhanced transparency from contractors, a new Chief Competition Officer position, and domestic origin requirements for food assistance programs — the American Economic Liberties Project released the following statement. The rule is the first in a series of forthcoming rules under the Packers and Stockyards Act.
Climate and Economic Justice Advocates Urge FTC to Block Big Oil Consolidation
November 8, 2023 — Today, the American Economic Liberties Project, along with Climate Power, Demand Progress, Sierra Club and eighteen additional signatories—a coalition of advocates for economic and climate justice—sent a letter to the Federal Trade Commission urging them to investigate and block recently proposed mega-acquisitions by Big Oil firms ExxonMobil and Chevron.
FSGG Approps Bill Must Support Enforcers, Not Kneecap Them
November 8, 2023 — With Congress set to debate the Fiscal Year 2024 Financial Services and General Government (FSGG) appropriations bill today—a bill containing several radical amendments to gut the funding of critical agencies and weaken important competition authorities—the American Economic Liberties released the following statement:
New CFPB Payment App Rule Will Protect Consumers and Competition
November 7, 2023 — In response to a new rule proposed by the Consumer Financial Protection Bureau (CFPB) that would subject digital payment apps to more regulatory scrutiny, the American Economic Liberties Project released the following statement.
FTC Takes Sweeping Action Against Big Pharma’s Sham Patent Game, Ensuring Inhalers, EpiPens, and More Are Affordable and Accessible
November 7, 2023 — The Federal Trade Commission (FTC) announced new action today to challenge 100+ patents of brand name inhalers, epinephrine auto injectors and more — which follows the Commission’s passage of a policy statement condemning improper listing of patents in the Food and Drug Administration’s (FDA) Orange Book. In response, the American Economic Liberties Project released the following statement: